Pages that link to "Q79329951"
Jump to navigation
Jump to search
The following pages link to Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium (Q79329951):
Displaying 50 items.
- Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer (Q26773664) (← links)
- Current Status of Robot-Assisted Radical Cystectomy: What is the Real Benefit? (Q26779973) (← links)
- Emerging critical role of molecular testing in diagnostic genitourinary pathology (Q27021371) (← links)
- Female with bladder cancer: what and why is there a difference? (Q28066115) (← links)
- Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider? (Q28066214) (← links)
- Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery (Q28074930) (← links)
- How to optimally manage elderly bladder cancer patients? (Q28076939) (← links)
- Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach (Q30455697) (← links)
- Laparoscopic versus open radical cystectomy in bladder cancer: a systematic review and meta-analysis of comparative studies (Q33623496) (← links)
- Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial. (Q33630045) (← links)
- The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells. (Q33844443) (← links)
- Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer (Q33888808) (← links)
- Role of pelvic lymphadenectomy in the treatment of bladder cancer: a mini review (Q33931385) (← links)
- Expression of cyclin d1 and its association with disease characteristics in bladder cancer (Q34005450) (← links)
- Critical review of prostate cancer predictive tools (Q34104562) (← links)
- High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer (Q34184763) (← links)
- Efficacy of robot-assisted radical cystectomy (RARC) in advanced bladder cancer: results from the International Radical Cystectomy Consortium (IRCC) (Q34337059) (← links)
- Bladder cancer in the elderly (Q34479053) (← links)
- Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1. (Q34487830) (← links)
- Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling (Q34505763) (← links)
- Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer (Q34563208) (← links)
- Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer (Q34626603) (← links)
- Staging and reporting of urothelial carcinoma of the urinary bladder (Q34984796) (← links)
- External beam radiation plus concurrent intra-arterial chemotherapy with low dose cisplatin for muscle invasive bladder cancer (Q34990822) (← links)
- The time from diagnosis of bladder cancer to radical cystectomy in Polish urological centres - results of CysTiming Poland study (Q35028256) (← links)
- Thiothymidine combined with UVA as a potential novel therapy for bladder cancer. (Q35034773) (← links)
- The effect of age and gender on bladder cancer: a critical review of the literature (Q35043055) (← links)
- Efficacy of (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography in restaging muscle-invasive bladder cancer following radical cystectomy. (Q35048726) (← links)
- Use of nomograms for predictions of outcome in patients with advanced bladder cancer (Q35076360) (← links)
- Rationale for an early detection program for bladder cancer (Q35125733) (← links)
- Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer. (Q35539470) (← links)
- Increased expression of L-selectin (CD62L) in high-grade urothelial carcinoma: A potential marker for metastatic disease (Q35548679) (← links)
- Best practice in the treatment of nonmuscle invasive bladder cancer (Q35688392) (← links)
- Perioperative outcomes after radical cystectomy at NCI-designated centres: Are they any better? (Q35777567) (← links)
- Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. (Q35860815) (← links)
- Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-Guérin (Q35898208) (← links)
- Decreased expression of protein tyrosine phosphatase non-receptor type 12 is involved in the proliferation and recurrence of bladder transitional cell carcinoma (Q38633196) (← links)
- Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder Cancer Network experience (Q36040572) (← links)
- High expression level of BLCA-4 correlates with poor prognosis in human bladder cancer (Q36092953) (← links)
- Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis (Q36117964) (← links)
- Extended pelvic lymph node dissection: before or after radical cystectomy? A multicenter study of the Turkish society of urooncology (Q36120392) (← links)
- Oncolytic viruses in the treatment of bladder cancer (Q36147934) (← links)
- Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible? (Q36170392) (← links)
- Impact of surgical margin status on the outcome of bladder cancer treated by radical cystectomy: a meta-analysis (Q36176989) (← links)
- Completeness of bladder cancer staging in the Danish Cancer Registry, 2004-2009. (Q36194019) (← links)
- Plasmacytoid urothelial carcinoma of the urinary bladder: a clinical pathological study and literature review (Q36196720) (← links)
- Disease-Free Survival at 2 and 3 Years is a Significant Early Surrogate Marker Predicting the 5-Year Overall Survival in Patients Treated with Radical Cystectomy for Urothelial Carcinoma of the Bladder: External Evaluation and Validation in a Cohort (Q36221402) (← links)
- Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies (Q36356386) (← links)
- Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling (Q36419132) (← links)
- Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort (Q36487162) (← links)